The news broke last month that at least one national retailer - whose targeted demographic group is adolescent girls and young women - was found to be selling potentially cancer-causing makeup. This revelation came in the midst of the holiday sales crush, when consumers were flocking to malls and stores for last-minute gifts for friends and loved ones.
Malignant mesothelioma is a disease often contracted from occupational exposure to asbestos. The latency period for the disease is approximately 20 to 40 years, sometimes as long as 71 years. Therefore, despite increased regulation of asbestos, more North Carolinians are discovering that they have mesothelioma due to their exposure to asbestos decades earlier.
North Carolinians would likely be interested in a new mesothelioma study. The study, conducted by Johns Hopkins and Drexel University, reveals that survivors of mesothelioma and other cancers may not be following appropriate dietary guidelines to increase their survivability. Participants in the study -- 53 survivors of breast, prostate and non-Hodgkin's lymphoma -- were asked to track their diets over three days.
Mesothelioma Awareness Day, established by Meso Foundation community members, will take place on September 26 for the 13th year in a row. The campaign is designed to bring awareness and funding to mesothelioma, a disease that claims the lives of thousands each year. The disease has a mortality rate of nearly 64 percent within one year.
A recent study by researchers at the MD Anderson Cancer Center confirms what many North Carolina residents suffering from mesothelioma already know -- mesothelioma patients benefit greatly from undergoing several forms of treatment. The study's researchers found that post-disease diagnosis patients, who undergo multimodal treatment, live almost twice as long as those who do not.
Mesothelioma patients may be disappointed to learn that a trial of a new mesothelioma drug, anetumab ravtansine, was stopped after the drug was proven to be less effective than an existing drug, vinorelbine. The results of Bayer's Phase II clinical trial showed that the new drug designed to treat recurrent malignant mesothelioma did not slow progression of mesothelioma better than vinorelbine and therefore the trial did not meet its primary endpoint.
Treatments for mesothelioma have become more abundant and more advanced in the last ten years. While there is still no cure, patients are living longer and studies into new treatments have provided encouraging results. One controversial procedure may be more of a viable option due to the utilization of modern technology. According to a renowned thoracic surgeon, robotic surgery may change the future of mesothelioma treatment.
North Carolina residents may be interested to hear that recently, cancer researchers analyzed patients with peritoneal surface cancers to determine if the interval between cytoreductive surgeries with heated hyperthermic intraperitoneal chemotherapy is a marker for survival. Fourteen percent of patients in the study had peritoneal mesothelioma, a form of malignant mesothelioma initially affecting the lining of the abdomen. The other patients had peritoneal appendiceal, colorectal or ovarian cancer-related tumors. The study concludes that patients who live longer between surgeries have a greater chance of longer survival overall.
A previous blog post discussed an ongoing trial (Keynote-028) of a promising new treatment for mesothelioma. The study aimed to examine the effects of Keytruda, a checkpoint inhibitor immunotherapy drug, on patients with mesothelioma. The U.S. Food and Drug Administration has now approved Keytruda for treatment of advanced or metastatic urothelial carcinoma, bringing it one step closer to becoming an approved treatment option for those with mesothelioma.
Thousands of people are diagnosed with mesothelioma each year. The latency period for mesothelioma is particularly long. Consequently, it has decades to establish itself in the body before disease diagnosis and treatment.